CSL Limited (OTCMKTS:CSLLY - Get Free Report) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 12,800 shares, a growth of 300.0% from the May 15th total of 3,200 shares. Based on an average trading volume of 139,400 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are sold short.
CSL Stock Down 2.0%
CSLLY stock traded down $1.60 during midday trading on Friday, reaching $77.54. The stock had a trading volume of 87,864 shares, compared to its average volume of 91,040. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18. The firm has a fifty day simple moving average of $78.24 and a two-hundred day simple moving average of $82.18. CSL has a 52-week low of $70.22 and a 52-week high of $109.00.
About CSL
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
